FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

NATCOPHARM

875
+27.1 (3.2%)
Updated 10:08 11/08 IST

NATCOPHARM Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for NATCOPHARM
Disclaimer
0% Bullish
0% Bearish

NATCOPHARM Buy or Sell - Brokerage Reports

No. of reports in last year
3
No. of analysts
2
Average Consensus Forecast
624.33
Consensus Potential
-37.40%
See NATCOPHARM Share Price Targets >>

NATCOPHARM Ratings

Long term NATCOPHARM rating by FrontPage users
5/5 (2 Ratings)
Find answers to all your questions on live NATCOPHARM message board: Is NATCOPHARM buy or sell? Should I buy NATCOPHARM shares? Why are NATCOPHARM shares falling? Should I invest in NATCOPHARM stock?

  1. Home
  2. NATCOPHARM Forum

NATCOPHARM Share Price Discussion


Type
Buy
Instrument
NATCOPHARM
Entry Price
₹802
Price@Trade
₹803.8
Target Price
₹848
Stop Price
₹760
Valid Till
Sep 10, 2020 3:20 AM
Margin
₹80,200 approx for 100 Qty
Status
Waiting for entry
Like
Reply
Bumblebee OPTION in CIPLA
Cipla rocking from.25 to 32 8000 per lot 🏆 #...

44😂😂
20k per lot 🏆
Awsome gains
Like
Reply

Type
Buy
Instrument
BANKNIFTY 13AUG20 22100 CE
Entry Price
₹260
Price@Trade
₹275.5
Target Price
₹375
Stop Price
₹170
Valid Till
Aug 11, 2020 3:20 AM
Margin
₹6,500 approx for 25 Qty
Status
Waiting for entry
Like
Reply

Type
Sell
Instrument
M&M AUG20 FUT
Entry Price
₹640.25
Price@Trade
₹640.25
Target Price
₹625
Stop Price
₹644
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹255,988.95 approx for 1400 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
BANKNIFTY 13AUG20 22000 PE
Entry Price
₹305
Price@Trade
₹310.4
Target Price
₹475
Stop Price
₹275
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹7,625,000 approx for 25000 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
SwingTraders Academy @rameswaran
Yesterday 4:14 AM

Update
Exited before entry
Price @ Update
₹305

Type
Buy
Instrument
WIPRO AUG20 FUT
Entry Price
₹279
Price@Trade
₹279.8
Target Price
₹281.5
Stop Price
₹276.5
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹213,673.6 approx for 3200 Qty
Status
Waiting for entry
Like
Reply
TradeAdda in TATAMOTORS
#TATAMOTORS For Educational Purposes Only . ...
Like
Reply
S
Reputation: 1,657 • Yesterday 4:13 AM
Sonu in NIFTY-BANK
#NIFTYBANK imp spot level for 10-Aug Trade are ...
Like
Reply

Type
Buy
Instrument
BAJAJELEC
Entry Price
₹448
Price@Trade
₹432.6
Target Price
₹500
Stop Price
₹400
Valid Till
Sep 10, 2020 3:20 AM
Margin
₹44,800 approx for 100 Qty
Status
Waiting for entry
Like
Reply

Type
Buy
Instrument
CIPLA
Entry Price
₹791.7
Price@Trade
₹791.7
Target Price
₹842.8
Stop Price
₹768.55
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹99,754.2 approx for 126 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
M&M
Entry Price
₹636
Price@Trade
₹635.9
Target Price
₹639
Stop Price
₹633
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹63,600 approx for 100 Qty
Status
Active
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 4:14 AM

Update
Trade Entered
Entry Price
₹636
B
Reputation: -6,237 • Yesterday 4:12 AM

Type
Sell
Instrument
SILVERM 31AUG20 FUT
Entry Price
₹74,993
Price@Trade
₹74,980
Target Price
₹74,500
Stop Price
₹75,350
Valid Till
Aug 10, 2020 11:20 AM
Margin
₹66,890.31 approx for 5 Qty
Status
Active
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 4:13 AM

Update
Trade Entered
Entry Price
₹74,993

Type
Buy
Instrument
AUROPHARMA
Entry Price
₹935
Price@Trade
₹935.5
Target Price
₹980
Stop Price
₹900
Valid Till
Sep 10, 2020 3:20 AM
Margin
₹9,350 approx for 10 Qty
Status
Active
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 4:13 AM

Update
Trade Entered
Entry Price
₹935
K
Reputation: 421 • Yesterday 4:12 AM

Type
Sell
Instrument
BHARATFORG
Entry Price
₹425.35
Price@Trade
₹425.35
Target Price
₹419
Stop Price
₹431
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹255,210 approx for 600 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
IPCALAB
Entry Price
₹2,050
Price@Trade
₹2,053.75
Target Price
₹2,100
Stop Price
₹2,000
Valid Till
Sep 10, 2020 3:20 AM
Margin
₹2,050 approx for 1 Qty
Status
Active
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 4:14 AM

Update
Trade Entered
Entry Price
₹2,050

Type
Buy
Instrument
TORNTPHARM AUG20 FUT
Entry Price
₹2,992.75
Price@Trade
₹2,992.75
Target Price
₹3,300
Stop Price
₹2,950
Valid Till
Aug 27, 2020 3:20 AM
Margin
₹368,473.13 approx for 500 Qty
Status
Active
Like
Reply

Type
Buy
Instrument
CRUDEOIL 19AUG20 FUT
Entry Price
₹3,135
Price@Trade
₹3,138
Target Price
₹3,155
Stop Price
₹3,115
Valid Till
Aug 10, 2020 11:20 AM
Margin
₹313,422.5 approx for 100 Qty
Status
Waiting for entry
Like
Reply
N
Reputation: 4,769 • Yesterday 4:11 AM
Rupee opens 2 paise down at 74.95 against dollar
​​The US dollar rose against its major crosses despite US employment growing at a slower pace considerably in July amid a resurgence in new Covid-19 infections.
The Economic Times
Like
Reply

Type
Buy
Instrument
ASIANPAINT
Entry Price
₹1,795.15
Price@Trade
₹1,795.8
Target Price
₹1,818.2
Stop Price
₹1,780.4
Valid Till
Aug 10, 2020 3:20 AM
Margin
₹244,140.4 approx for 136 Qty
Status
Active
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 4:12 AM

Update
Trade Entered
Entry Price
₹1,795.15
B
Reputation: -29,326 • Yesterday 4:10 AM

Type
Sell
Instrument
CIPLA AUG20 FUT
Entry Price
₹795
Price@Trade
₹794.5
Target Price
₹760
Stop Price
₹811
Valid Till
Aug 11, 2020 3:20 AM
Margin
₹217,987.9 approx for 1300 Qty
Status
Active
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 4:11 AM

Update
Trade Entered
Entry Price
₹795
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • NATCOPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization13,915.91
    Enterprise Value13,916.81
    Price to Earnings19.94
    Price to Book Value4.45
    Return on Capital Employed0.27
    Return on Equity0.22
    Face Value2
    Dividend Yield0.01
  • NATCOPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    9-Mar-20Geojit Financial ServicesSell534
    14-Feb-20Nirmal BangAccumulate685
    13-Aug-19Nirmal BangBuy654
    9-Aug-19AnandRathiBuy763
    31-May-19Geojit Financial ServicesSell487
    NATCOPHARM Brokerage Price Target
  • NATCOPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 10785.7859783.05847.9
    Aug 7762.7794.8760781.75
    Aug 6785.45789755758.25
    Aug 5815815775785.45
    Aug 4810815.75770786.1
  • NATCOPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹732.64
    30 Day Moving Average₹708.83
    50 Day Moving Average₹672.64
    100 Day Moving Average₹623.3
    200 Day Moving Average₹614.37
  • NATCOPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,0912,002.80.04
    Operating Profit9286920.34
    Profit Before Tax888634.10.4
    Net Income698494.80.41
  • NATCOPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds3,1261,699.70.84
    Total Liabilities612648.4-0.06
    Total Assets3,7372,348.10.59
  • NATCOPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity476329.80.44
    Cash from Investing Activity-1,131-290.62.89
    Cash from Financing Activity652-170.2-4.83
    Net Cash Flow-3-131-0.98
  • NATCOPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.190.21
    Return on Equity0.220.29
    Return on Capital Employed0.270.34
  • NATCOPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue1.92
    3 Year CAGR Growth in Operating Profit3.35
    3 Year CAGR Growth in EBIDTA3.26
    3 Year CAGR Growth in Net Income3.56
    3 Yr CAGR Growth - Diluted EPS-0.18
  • NATCOPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.75
    5 Year CAGR Growth in Operating Profit5.39
    5 Year CAGR Growth in EBIDTA5.15
    5 Year CAGR Growth in Net Income7.93
    3 Yr CAGR Growth - Diluted EPS0.52
  • NATCOPHARM - Recent News

    keyboard_arrow_down
    NewsBot
    Jul 31 3:23 AM
    Piramal Enter Standalone June 2020 Net Sales at Rs 817.41 crore, down 6.26% Y-o-Y
    Moneycontrol
    NewsBot
    Jul 31 3:23 AM
    Piramal Enter Consolidated June 2020 Net Sales at Rs 2,937.34 crore, down 16.23% Y-o-Y
    Moneycontrol
    NewsBot
    Jul 30 9:48 AM
    Piramal Enterprises Q1 net profit up 11% at Rs 496 crore
    Moneycontrol
    NewsBot
    Jul 10 2:08 AM
    Ajay Piramal says liquidity isn't a problem for good NBFCs
    Moneycontrol
    NewsBot
    Jul 10 6:21 AM
    Natco Pharma's Canadian unit signs pact with Celgene for cancer treatment drug
    The Economic Times
    NewsBot
    Jun 30 10:53 AM
    Buy Piramal Enterprises; target of Rs 1600: Motilal Oswal
    Moneycontrol
    NewsBot
    Jun 30 7:43 AM
    Buy Piramal Enterprises; target of Rs 40: Motilal Oswal
    Moneycontrol
    NewsBot
    Jun 29 3:53 AM
    Piramal Enterprises shares gain after Carlyle Group buys 20% stake in Piramal Pharma
    Moneycontrol
    NewsBot
    Jun 27 9:18 AM
    Piramal says Carlyle proceeds will help fund pharma acquisitions, organic growth
    Moneycontrol
    NewsBot
    Jun 23 12:28 PM
    Piramal Enterprises to raise up to Rs 2,590 crore through bonds
    Moneycontrol
  • NATCOPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020